Clinical Trial: Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07291037) titled 'Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations' on Oct. 28.

Brief Summary: TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).

Study Start Date: Oct. 31

Study Type: INTERVENTIONAL

Condition: Non-small Cell Lung Cancer (NSCLC)

Intervention: DRUG: Datopotamab deruxtecan (Dato-DXd)

Dato-DXd adm...